Cashu
Salarius Pharmaceuticals Secures Nasdaq Extension to Address Compliance and Innovate Cancer Treatments
1 day ago
Stocks
Health Care
slrx
Salarius Pharmaceuticals
SLRX
+0.08 (+7.87%)
1.165
USD
At close at Jun 20, 20:40 UTC
Overview
Loading chart...
Key Stats
Market Cap
2.01M
Dividend Yield
0.00%
P/E Ratio
-0.36
EPS
-7.07
Revenue
-
Avg. Volume
29.93K
About
What does SLRX do?
Salarius Pharmaceuticals, a clinical-stage biopharmaceutical company based in Houston, Texas, focuses on developing innovative cancer treatments, including seclidemstat and SP-3164. The company went public on January 29, 2015.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.